Table 2 Staining characteristics of the patient cohort.
From: Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma
Marker | Diagnosis/intensity | Negative (%) | Weak (%) | Intermediate (%) | Strong (%) | Positive (%) | # of Tumors (%) |
|---|---|---|---|---|---|---|---|
Ki-67 | sPGL | 0 (0) | 0 (0) | 4 (31) | 9 (69) | 13 (100) | 13 (100) |
HN-PGL | 0 (0) | 0 (0) | 2 (16) | 11 (84) | 13 (100) | 13 (100) | |
PCC | 2 (2) | 13 (10) | 59 (48) | 49 (40) | 121 (98) | 123 (100) | |
HIF-1α | sPGL | 11 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 11 (100) |
HN-PGL | 8 (62) | 5 (38) | 0 (0) | 0 (0) | 5 (38) | 13 (100) | |
PCC | 106 (91) | 7 (6) | 1 (1) | 3 (2) | 11 (9) | 117 (100) | |
HIF-2α-N | sPGL | 8 (61) | 4 (31) | 1 (8) | 0 (0) | 5 (39) | 13 (100) |
HN-PGL | 1 (8) | 7 (58) | 1 (8) | 3 (26) | 11 (92) | 12 (100) | |
PCC | 97 (82) | 20 (16) | 2 (2) | 0 (0) | 22 (18) | 119 (100) | |
HIF-2α-C | sPGL | 0 (0) | 4 (31) | 7 (54) | 2 (15) | 13 (100) | 13 (100) |
HN-PGL | 0 (0) | 1 (8) | 5 (42) | 6 (50) | 12 (100) | 12 (100) | |
PCC | 15 (13) | 65 (54) | 33 (28) | 6 (5) | 104 (87) | 119 (100) |
